Cidara Therapeutics reports Q2 results

2 hours ago 2
  • Cidara Therapeutics press release (NASDAQ:CDTX): Q2 Cash, cash equivalents and restricted cash totaled $516.9 million as of June 30, 2025, compared with $196.2 million as of December 31, 2024.
  • Collaboration revenue was zero for the three and six months ended June 30, 2025, compared to $0.3 million

Recommended For You

More Trending News

Read Entire Article